KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Raw Materials (2018 - 2025)

Historic Raw Materials for Alnylam Pharmaceuticals (ALNY) over the last 8 years, with Q4 2025 value amounting to $14.2 million.

  • Alnylam Pharmaceuticals' Raw Materials fell 4081.37% to $14.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $14.2 million, marking a year-over-year decrease of 4081.37%. This contributed to the annual value of $14.2 million for FY2025, which is 4081.37% down from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Raw Materials of $14.2 million as of Q4 2025, which was down 4081.37% from $22.3 million recorded in Q3 2025.
  • Alnylam Pharmaceuticals' 5-year Raw Materials high stood at $65.2 million for Q3 2021, and its period low was $14.2 million during Q4 2025.
  • In the last 5 years, Alnylam Pharmaceuticals' Raw Materials had a median value of $22.6 million in 2024 and averaged $26.6 million.
  • In the last 5 years, Alnylam Pharmaceuticals' Raw Materials crashed by 7675.07% in 2021 and then soared by 5124.71% in 2022.
  • Over the past 5 years, Alnylam Pharmaceuticals' Raw Materials (Quarter) stood at $14.8 million in 2021, then surged by 51.25% to $22.3 million in 2022, then increased by 4.62% to $23.3 million in 2023, then increased by 2.65% to $24.0 million in 2024, then tumbled by 40.81% to $14.2 million in 2025.
  • Its Raw Materials was $14.2 million in Q4 2025, compared to $22.3 million in Q3 2025 and $22.9 million in Q2 2025.